ArticlePloS one2025
Anti-aging effect of low molecular weight recombinant humanized collagen on photo-aging by activating adherence junction signaling pathways.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- In vivo assessment of collagen transdermal absorption in murine and human skin using photoacoustics microscopy.Scientific reports · 2026Article
- Effect of Gelatin-Peptide Complex from Sturgeon Skin on Behavioral, Antioxidant, and Neuroprotective Functions in D-Galactose-Induced Aging Mice: Thermal Degradation vs. Enzymatic Hydrolysis.Foods (Basel, Switzerland) · 2026Article
- Therapeutic potential of recombinant human collagen XVII in blue light-induced skin photoaging: preserving epidermal-dermal structural integrity and functional homeostasis.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin aging is characterized by a loss of collagen. Collagen stimulates the secretion of extracellular matrix (ECM) components by skin fibroblasts, contributing to anti-wrinkle and skin-firming effects in cosmetic applications. However, the skin barrier poses a significant challenge to collagen absorption, hindering its dermal functionality. Rapid advancements in synthetic biology have enabled the development of recombinant human collagen (RHC) with controllable sequence and molecular weight, enhancing its potential cosmetic applications. Nonetheless, research on the ability of RHC to penetrate the skin and exert anti-aging effects remains limited, and its underlying mechanisms are largely unexplored. To address this gap, we selected low molecular weight recombinant human collagen peptide (LRHC) and evaluated its skin permeability and anti-aging mechanisms. Findings indicated that LRHC significantly promoted fibroblast proliferation and enhanced the transcription of collagen types I and type III. Furthermore, in photoaged nude mouse models, LRHC upregulated the expression of key basement membrane components, including collagen type IV (COL4), collagen type VII (COL7), collagen type XVII (COL17), integrin β4 (ITGB4), and laminin-332 (LN332, formerly LN5), resulting in increased collagen fiber density. Notably, LRHC demonstrated a dermal permeability rate of 74.7 ± 14.2% after 8 hours. Transcriptome sequencing revealed that LRHC may maintain cytoskeletal structure through activation of adherens junction signaling pathways and promote extracellular matrix (ECM) production through activation of transforming growth factor-beta (TGF-β) signaling pathways, thereby achieving anti-aging efficacy.. These findings confirm that LRHC can penetrate the dermis and exert anti-aging effects on skin, potentially through mechanisms mediated by adherens junction signaling pathways. As a functional active ingredient with anti-aging properties, LRHC holds significant potential for cosmetic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.